[
  {
    "name": "Pembrolizumab (Keytruda)",
    "mechanism": "Immune checkpoint inhibitor",
    "IC50": "0.12 nM",
    "side_effects": "Mild to moderate immune-related adverse events",
    "clinical_evidence": "Phase III KEYNOTE-189"
  },
  {
    "name": "Erlotinib",
    "mechanism": "EGFR inhibitor",
    "IC50": "0.08 nM",
    "side_effects": "Rash, diarrhea",
    "clinical_evidence": "Phase II study in NSCLC"
  }
]
